Human-friendly, Omni-channel, and AI-powered Customer Engagement in Life Sciences

How the Next Generation Customer Engagement in Life Sciences will look like in the Hybrid Era

Managing change and uncertainty for customers has been a top priority for the life sciences and healthcare industry for the last couple of years amidst the global pandemic. With changing customer preferences and new possibilities of digital access, the life science industry is rapidly evolving towards hybrid engagement. At Tact.ai we have been observing and adapting to this change within the industry landscape by building solutions that help life sciences organizations work more effectively with healthcare professionals (HCPs) and healthcare organizations.

It's essential to note that HCPs over the course of the pandemic have adapted to new tools and technologies. The hesitation about virtual meetings and virtual collaboration is long gone, and in fact, over 87% of HCPs want either all virtual or a mix of virtual and in-person meetings even after the pandemic ends as per an Accenture survey. It’s clear that the future of pharma engagement coveted by HCPs is hybrid, omnichannel, and most importantly adding value to their daily lives by virtue of meaningful, scientific conversations and collaborations.

Our customer engagement platform is specifically designed to create an omnichannel, holistic, and outcome-centric customer engagement experience when it comes to pharma, biotech, and medical devices companies. It encompasses the hybrid consumer engagement journey by combining and aligning the face-to-face, phone, email, video, chat, and self-service modes of engagement. The Tact customer engagement platform helps life sciences companies deliver personalization at scale while diversifying their technology stack with best-in-class tools.

The Tact AI-powered customer engagement platform empowers life sciences teams, to work with their customers in newer ways to drive better outcomes in every interaction across the customer journey. It boosts field productivity by enabling field teams to be nimbler and more effective. It empowers the customer to engage ‘on-demand 'and through their preferred channel driving a true, no-friction, omnichannel experience.  

With a newer approach towards the life science industry and the industry’s confidence in Tact with a new round of equity financing totaling $33 million including investments from Novartis' dRx Capital, McKesson Ventures, and Eli Lilly, we are all set to bring the next generation of customer engagement to life sciences.The strategic investments from the life sciences industry as well as our existing investors including Microsoft’s M 12, and Salesforce Ventures, highlights the ever-increasing demand for hybrid engagement and the need for life sciences organizations to collaborate more effectively with healthcare professionals.

Read more on Tact’s latest round of funding and collaboration with Novartis dRx Capital, McKesson Ventures, and Eli Lilly Here!

‍